Migraine
Conditions
Brief summary
Difference between groups receiving atorvastatin 40 mg daily and placebo in change from baseline in number of migraine days per 4 weeks
Detailed description
Difference between groups receiving atorvastatin 40 mg daily and placebo in change from baseline in number of headache per 4 weeks, Difference in change from baseline between groups receiving atorvastatin 20 mg daily and placebo in number of days with headache per 4 weeks,, Number of responders (≥ 50% decrease in migraine days compared with baseline) between repectively Atorvastin 40 mg, Atorvastatin 20 mg and placebo
Interventions
DRUGATORVASTATIN
DRUGPLACEBO
Sponsors
St. Olavs Hospital HF, St. Olavs Hospital HF
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference between groups receiving atorvastatin 40 mg daily and placebo in change from baseline in number of migraine days per 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference between groups receiving atorvastatin 40 mg daily and placebo in change from baseline in number of headache per 4 weeks, Difference in change from baseline between groups receiving atorvastatin 20 mg daily and placebo in number of days with headache per 4 weeks,, Number of responders (≥ 50% decrease in migraine days compared with baseline) between repectively Atorvastin 40 mg, Atorvastatin 20 mg and placebo | — |
Countries
Norway
Outcome results
None listed